S

    SeaStar Medical Holding Corporation (ICU)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.12
    +0.03 (+0.97%)

    Market Cap: $13.62M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(8/14)
    Avg Surprise
    -36.86%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.95
    Range$-0.95 - $-0.95
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    2
    30d
    EPS Estimate Drift
    90d ago$-0.90+5.8%
    60d ago$-0.90+5.8%
    30d ago$-0.90+5.8%
    7d ago$-0.90+5.8%
    Current$-0.95
    Revenue Consensus
    $500000
    Range$500000 - $500000
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.92
    Range$-0.92 - $-0.92
    1 analysts
    Revenue Consensus
    $576000
    Range$576000 - $576000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.92---
    Sep 26EST
    		-$-0.95---
    Jun 26
    		$-0.91$-0.91+0.00%Beat+49.4%
    Mar 26
    		$-0.90$-0.82-9.76%Miss+79.5%
    Dec 25
    		$-0.80$-1.01+21.18%Beat+11.1%
    Sep 25
    		$-1.30$-1.50+13.33%Beat+88.2%
    Jun 25
    		$-1.80N/A+58.14%Beat+82.5%
    Mar 25
    		$-4.40$-5.20+15.38%Beat+90.7%
    Dec 24
    		$-0.90$-0.18-400.00%Miss-309.1%
    Sep 24
    		$-11.00$-11.30+2.65%Beat+88.1%
    Jun 24
    		$-10.30$-14.10+26.95%Beat+83.5%
    Mar 24
    		$-47.50$-37.50-26.67%Miss+52.5%
    Dec 23
    		$-0.22$-0.13-69.23%Miss+89.2%
    Sep 23
    		$-92.50$-62.50-48.00%Miss-184900.0%
    Jun 23
    		$-62.50$-62.50+0.00%Beat-446528.6%
    Mar 23
    		$-100.00$-50.00-100.00%Miss-1000100.0%
    Dec 22
    		$-2.04N/AN/ABeat-192.3%
    Sep 22
    		$-0.05N/AN/ABeat-350.0%
    Jun 22
    		$0.01N/AN/ABeat+109.3%
    Mar 22
    		$0.01N/AN/ABeat-94.4%
    Dec 21
    		$2.22N/AN/ABeat-
    Sep 21
    		$0.02N/AN/ABeat-
    Jun 21
    		$-0.15N/AN/ABeat-
    Mar 21
    		$0.18N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.80EV/EBITDA-8.13x
    Price/FCF-0.93xFCF Yield-107.46%
    Profitability
    Profit Margin0.00%Operating Margin-616.00%
    ROE-356.90%ROIC-315.82%
    Financial Health
    Debt/Equity0.03xInterest CoverageN/A
    Current Ratio1.89xQuick Ratio1.87x
    Trading Statistics
    Beta-1.04Avg Volume69.38K
    52-Week High$12.5052-Week Low$2.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.21
    SMA 20$3.25
    SMA 50$3.68
    SMA 200$3.29
    EMA 10$3.18
    EMA 20$3.28
    EMA 50$3.48
    EMA 200$4.31

    MACD

    Line: -0.14Signal: -0.14Hist: 0.00

    ADX

    ADX: 9.9+DI: 18.5-DI: 21.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down28.0
    PSAR$3.65

    Bollinger Bands

    Upper Band$3.61
    Lower Band$2.89
    %B Position2233%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    40.6

    Momentum Oscillators

    Stoch %K9.9
    Stoch %D10.3
    Williams %R-86.3
    ROC (10d)-4.0%
    Momentum-0.13
    CCI (20d)-76.7
    MFI (14d)35.7

    Volatility Measures

    ATR (14d)$0.23(7.5%)
    StdDev (20d)0.18
    Hist Vol73.2%(High)

    Volume Flow

    VWAP$3.11
    OBV286.2M
    AD Line67.7B
    CMF (20d)-0.149

    Volume Metrics

    Avg Vol (20d)70.5K
    Vol Ratio0.5x(Low)
    VWMA (20d)$3.32

    Pivot Points

    R3$3.29
    R2$3.22
    R1$3.16
    Pivot Point$3.09
    S1$3.03
    S2$2.96
    S3$2.90

    Advanced Oscillators

    TSI-16.75
    Ultimate Osc33.8
    KST-135.87

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$615,000$495,000$420,000$183,000$338,000$293,000$67,000$68,000$0$0$0$0
    Cost of Revenue$54,000$46,000$12,000$14,000$27,000$0$0$0$0$0N/A$0
    Gross Profit$561,000$449,000$408,000$169,000$311,000$293,000$67,000$68,000$0$0N/A$0
    Operating Expenses$4.35M$4.05M$3.43M$3.75M$2.07M$4.12M$4.83M$4.52M$4.67M$3.95M$2.94M$2.94M
    R&D$2.52M$2.34M$2.20M$1.85M$1.04M$2.43M$2.74M$2.34M$2.33M$1.70M$1.18M$1.09M
    SG&A$1.83M$1.71M$1.23M$1.90M$1.03M$1.68M$2.10M$2.19M$2.33M$2.25M$1.76M$1.85M
    Operating Income$-3,791,000$-3,603,000$-3,018,000$-3,579,000$-1,756,000$-3,822,000$-4,767,000$-4,456,000$-4,669,000$-3,950,000$-2,937,000$-2,942,000
    Interest Income$69,000$91,000$125,000$107,000$45,000$48,000$18,000$58,000$25,000$0$0$0
    Interest Expense$8,000$6,000$11,000$0$9,000$11,000$-253,000$272,000$82,000$143,000$199,000$5.17M
    Income Before Tax$-3,730,000$-3,518,000$-2,904,000$-3,472,000$-2,002,000$-3,769,000$-4,419,000$-4,478,000$-3,233,000$-12,697,000$-9,462,000$-7,232,000
    Income Tax Expense$0$3,000$0$0$0$3,000$0$0$3,000$0$-5,000$0
    Net Income$-3,730,000$-3,521,000$-2,904,000$-3,472,000$-2,002,000$-3,772,000$-4,419,000$-4,478,000$-3,236,000$-12,697,000$-9,457,000$-7,232,000
    EBITDA$-3,783,000$-3,597,000$-3,018,000$-3,579,000$-2,031,000$-3,795,000$-4,690,000$-4,219,000$-3,146,000$-12,527,000$-9,252,000$-2,045,000
    EBIT$-3,791,000$-3,603,000$-3,018,000$-3,579,000$-2,038,000$-3,806,000$-4,690,000$-4,264,000$-3,176,000$-12,554,000$-9,263,000$-2,059,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ICU

    News

    SeaStar Medical Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

    SeaStar Medical Holding Corporation announced its financial results for the second quarter and six months ended June 30, 2026. For the second quarter, the company reported sales of USD 0.615 million and a net loss of USD 3.73 million. Over the six-month period, sales reached USD 1.11 million, with a net loss of USD 7.25 million.

    www.marketscreener.com•8/13/26•
    Neutral

    SeaStar Medical Q2 Results: Revenue up 82% YoY to $0.6 million

    SeaStar Medical (NASDAQ: ICU) reported an 82% year-over-year revenue increase to $0.6 million in Q2 2026, driven by demand for its pediatric AKI therapy, QUELIMMUNE. Despite this growth, the company's net loss widened to $3.7 million due to increased R&D spending on its adult AKI trial and higher administrative costs. Cash reserves declined significantly, highlighting the need for capital management as it pursues broader market approval.

    scanx.trade•8/13/26•
    Somewhat-Bearish

    Earnings call transcript: SeaStar Medical misses Q2 2026 forecasts as stock falls

    SeaStar Medical reported a wider-than-expected loss and lower revenue for Q2 2026, leading to a stock decline despite an 82% increase in QUELIMMUNE therapy sales year-over-year. The company's NEUTRALIZE-AKI adult trial enrollment is progressing, with completion expected by year-end 2026 or early 2027, and management remains focused on expanding its pediatric market penetration and preparing for potential adult market entry. Investors reacted negatively to the earnings miss and revenue shortfall, though the company maintains a positive outlook for its full-year revenue target and regulatory milestones.

    Investing.com•8/12/26•
    Bearish

    SeaStar Medical (ICU) grows QUELIMMUNE sales but warns on going concern

    SeaStar Medical (ICU) reported increased net revenue from its FDA-approved pediatric QUELIMMUNE therapy for acute kidney injury, reaching $615,000 in Q2 2026 and $1.11 million year-to-date. Despite this growth, the company remains deeply loss-making with a net loss of $3.7 million for the quarter and $7.3 million for the first half of 2026. Cash reserves have declined to $7.0 million, and management has expressed substantial doubt about the company's ability to continue as a going concern without additional equity financing.

    Stock Titan•8/12/26•
    Somewhat-Bearish

    SEASTAR MEDICAL HOLDING ($ICU) Releases Q2 2026 Earnings

    SEASTAR MEDICAL HOLDING ($ICU) announced its Q2 2026 earnings, reporting -$0.91 per share, which beat estimates. The company also surpassed revenue expectations with $620,000. Following the earnings release, the stock experienced a -2.96% change after market close, and the article also details recent hedge fund activity related to ICU stock.

    Quiver Quantitative•8/12/26•
    Somewhat-Bullish

    Frequently Asked Questions About ICU

    Does ICU pay dividends?
    SeaStar Medical Holding Corporation (ICU) does not currently pay a regular dividend.
    What is ICU's market cap?
    SeaStar Medical Holding Corporation (ICU) has a market capitalization of $13.62M with a current stock price of $3.12.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In